Medical Cannabis Shows Promise in Dentistry for Pain and Inflammation, Review Finds

A review of 59 studies by Brazilian researchers indicates that medical cannabis has therapeutic potential in dentistry, particularly for orofacial pain, refractory periodontal diseases, and burning mouth syndrome. The authors call for more clinical trials and better regulation to ensure equitable access.

Medical cannabis has promising therapeutic potential in dentistry, according to a new scientific review published in Fitos Journal. The paper, authored by researchers from the Health Department of the Federal District, School of Public Health of the Federal District, and Higher Education Institute of Brasília, analyzed 59 previously published studies and found theoretical and scientific support for using medicinal cannabis in dental care.

The review highlights that endocannabinoid receptors are present throughout the oral cavity, including the oral mucosa, dental pulp, periodontal tissues, salivary glands, and temporomandibular joints. Activating these receptors could provide targeted pain relief, reduce inflammation, and offer antimicrobial effects, the authors said.

One study included in the review concluded that cannabinoids have a therapeutic effect in reducing pain perception, especially for trigeminal neuralgia, persistent idiopathic facial pain, burning mouth syndrome, and post-herpetic neuralgia. The authors noted that orofacial pain is among the most common conditions in dental care, and cannabis appears to be an important ally in treating these discomforts, potentially enhancing or even replacing existing medications.

The paper also identified potential applications in periodontics, bruxism, and management of oral mucositis. However, the researchers cautioned that while current evidence is promising and cannabis is considered a safe therapy, randomized controlled trials are needed to more robustly confirm its efficacy and safety.

The authors also pointed to regulatory challenges, noting a lack of adequate regulation in Brazil and elsewhere that can lead to inequalities in access, favoring those who can afford expensive products. They also highlighted the lack of standardization in dosing due to individual variability in the endocannabinoid system.

This review adds to prior research on cannabis and oral health, including studies on CBD mouthwash for oral microbiome homeostasis and a 2023 paper finding that a single dose of CBD is as potent as current analgesic regimens for emergency dental pain.